Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SailPoint Inc. Common Stock (SAIL) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance

SailPoint Inc. Common StockTrade
SELLAS Life Sciences Group Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

SailPoint Inc. Common Stock vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? SailPoint Inc. Common Stock trades at $19.03 (market cap $11.06B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.78 (market cap $2.51B). The key difference: SailPoint Inc. Common Stock is far larger — about 4.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is more actively traded (6,359,048 versus 3,269,663). Which is the better fit depends on your goals — on Pluang, investors hold SailPoint Inc. Common Stock for 0 Days and SELLAS Life Sciences Group Inc. Common Stock for 0 Days on average.

SAILSLS
Market Cap
$11.06B$2.51B
Volume
3,269,6636,359,048
Sector
TechnologyHealth
52-Week High
$22.85$15.46
52-Week Low
$10.49$1.39
Typical Hold Time
0 Days0 Days
Enterprise Value
$10.76B$2.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SailPoint Inc. Common Stock

No Aura AI signal available yet.

SELLAS Life Sciences Group Inc. Common Stock

SELLAS Life Sciences (SLS) trades at $12.41, up 4.02% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported no revenue in 2025, with a net loss of $26.86 million, negative ROE and ROA, and a high P/B ratio of 18.2. Recent news includes a law firm investigation into investor claims and positive preclinical data for SLS009 in pancreatic cancer models presented at the AACR conference.

The outlook hinges on upcoming clinical trial results, particularly the Phase 3 REGAL trial for GPS in AML, with topline data expected in Q4 2026. While analyst consensus is unanimously bullish, significant risks include the binary nature of trial outcomes, ongoing legal scrutiny, and persistent negative profitability metrics. The stock's recent surge of ~300% year-to-date reflects high investor optimism but also heightened volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SAIL
100% Buy0% Sell
Avg holding period · 0 Days
SLS
100% Buy0% Sell
Avg holding period · 0 Days

About SailPoint Inc. Common Stock

SailPoint, Inc. develops identity security software that helps enterprises manage and govern access to applications and data across users, machines, and AI agents. Its unified identity security platform combines automation and intelligence to control identity-related risk at scale for large organizations.

Read more on SAIL →

About SELLAS Life Sciences Group Inc. Common Stock

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.

Read more on SLS →